These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30396808)

  • 1. Immunotherapy in Gliomas.
    Weant MP; Jesús CM; Yerram P
    Semin Oncol Nurs; 2018 Dec; 34(5):501-512. PubMed ID: 30396808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for glioma: Current management and future application.
    Xu S; Tang L; Li X; Fan F; Liu Z
    Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
    Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
    Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.
    Selznick LA; Shamji MF; Fecci P; Gromeier M; Friedman AH; Sampson J
    Neurosurg Rev; 2008 Apr; 31(2):141-55; discussion 155. PubMed ID: 18259789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dendritic cell vaccines in neurological oncology].
    Chekhonin IV; Kobyakov GL; Gurina OI
    Zh Vopr Neirokhir Im N N Burdenko; 2020; 84(1):76-85. PubMed ID: 32207746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.
    Sferruzza G; Consoli S; Dono F; Evangelista G; Giugno A; Pronello E; Rollo E; Romozzi M; Rossi L; Pensato U
    Neurol Sci; 2024 Jun; 45(6):2561-2578. PubMed ID: 38308708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy Against Gliomas: is the Breakthrough Near?
    Lukas RV; Wainwright DA; Horbinski CM; Iwamoto FM; Sonabend AM
    Drugs; 2019 Nov; 79(17):1839-1848. PubMed ID: 31598900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The yellow fever vaccine as a new cancer treatment?].
    Petithomme T; Grard M; Fonteneau JF; Boisgerault N
    Med Sci (Paris); 2020 Dec; 36(12):1216-1217. PubMed ID: 33296641
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and Translational Advances in Glioma Immunotherapy.
    Bunse L; Bunse T; Krämer C; Chih YC; Platten M
    Neurotherapeutics; 2022 Oct; 19(6):1799-1817. PubMed ID: 36303101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult immuno-oncology: using past failures to inform the future.
    Rahman M; Sawyer WG; Lindhorst S; Deleyrolle LP; Harrison JK; Karachi A; Dastmalchi F; Flores-Toro J; Mitchell DA; Lim M; Gilbert MR; Reardon DA
    Neuro Oncol; 2020 Sep; 22(9):1249-1261. PubMed ID: 32391559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy against gliomas].
    Sahm K; Weiss T
    Nervenarzt; 2024 Feb; 95(2):111-116. PubMed ID: 38169045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Difficulties and prospects in the immunotherapy of gliomas].
    Mangel L; Najbauer J; Kajtár B; Pongrácz EJ
    Magy Onkol; 2019 Sep; 63(3):217-223. PubMed ID: 31533142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas - results.
    Rynda AY; Rostovthev DM; Zabrodskaya YM; Olyushin VE
    J Neurooncol; 2024 Jan; 166(2):309-319. PubMed ID: 38227144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational Models in Glioma Immunotherapy Research.
    Ren AL; Wu JY; Lee SY; Lim M
    Curr Oncol; 2023 Jun; 30(6):5704-5718. PubMed ID: 37366911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses.
    Kamrani A; Nasiri H; Hassanzadeh A; Ahmadian Heris J; Mohammadinasab R; Sadeghvand S; Sadeghi M; Valedkarimi Z; Hosseinzadeh R; Shomali N; Akbari M
    Cell Commun Signal; 2024 Jan; 22(1):56. PubMed ID: 38243252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Immunotherapy in the Treatment of Cancer.
    Kottschade LA
    Semin Oncol Nurs; 2019 Oct; 35(5):150934. PubMed ID: 31477413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
    Thompson JA; Schneider BJ; Brahmer J; Achufusi A; Armand P; Berkenstock MK; Bhatia S; Budde LE; Chokshi S; Davies M; Elshoury A; Gesthalter Y; Hegde A; Jain M; Kaffenberger BH; Lechner MG; Li T; Marr A; McGettigan S; McPherson J; Medina T; Mohindra NA; Olszanski AJ; Oluwole O; Patel SP; Patil P; Reddy S; Ryder M; Santomasso B; Shofer S; Sosman JA; Wang Y; Zaha VG; Lyons M; Dwyer M; Hang L
    J Natl Compr Canc Netw; 2022 Apr; 20(4):387-405. PubMed ID: 35390769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and prospects of mRNA vaccines in cancer immunotherapy.
    Liu Y; Yan Q; Zeng Z; Fan C; Xiong W
    Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189068. PubMed ID: 38171406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses.
    Chhabra N; Kennedy J
    J Med Toxicol; 2022 Jan; 18(1):43-55. PubMed ID: 33821435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Education Issues and Strategies Associated With Immunotherapy.
    Lasa-Blandon M; Stasi K; Hehir A; Fischer-Cartlidge E
    Semin Oncol Nurs; 2019 Oct; 35(5):150933. PubMed ID: 31481275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.